Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR
Autonomix Medical (NASDAQ: AMIX) announced that its technology and early proof-of-concept study results will be showcased at EuroPCR, a leading interventional cardiovascular medicine conference in Paris, France from May 20-23, 2025.
The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain Elpis Study', will be featured during PCR Innovators Day. The company's Chief Medical Officer, Dr. Robert S. Schwartz, will be the presenting author of the poster, highlighting Autonomix's developments in precision nerve-targeted treatments.
Autonomix Medical (NASDAQ: AMIX) ha annunciato che la sua tecnologia e i risultati preliminari dello studio proof-of-concept saranno presentati al EuroPCR, una conferenza di riferimento sulla medicina cardiovascolare interventistica che si terrà a Parigi, Francia, dal 20 al 23 maggio 2025.
La presentazione, intitolata 'Ablazione neurale RF transvascolare con catetere per il dolore severo da cancro al pancreas - Studio Elpis', sarà parte del PCR Innovators Day. Il Chief Medical Officer dell’azienda, il Dr. Robert S. Schwartz, sarà l’autore della presentazione del poster, evidenziando gli sviluppi di Autonomix nei trattamenti di precisione mirati ai nervi.
Autonomix Medical (NASDAQ: AMIX) anunció que su tecnología y los resultados preliminares de su estudio proof-of-concept serán presentados en el EuroPCR, una conferencia líder en medicina cardiovascular intervencionista que se celebrará en París, Francia, del 20 al 23 de mayo de 2025.
La presentación, titulada 'Ablación neural RF transvascular basada en catéter para el dolor severo del cáncer de páncreas - Estudio Elpis', formará parte del PCR Innovators Day. El Director Médico de la compañía, el Dr. Robert S. Schwartz, será el autor de la presentación del póster, destacando los avances de Autonomix en tratamientos de precisión dirigidos a los nervios.
Autonomix Medical (NASDAQ: AMIX)는 2025년 5월 20일부터 23일까지 프랑스 파리에서 열리는 주요 심혈관 중재 치료 학회인 EuroPCR에서 자사의 기술과 초기 개념 증명 연구 결과를 선보일 것이라고 발표했습니다.
'중증 췌장암 통증을 위한 카테터 기반 경혈관 RF 신경 소작술 엘피스 연구'라는 제목의 발표는 PCR Innovators Day에서 진행됩니다. 회사의 최고 의료 책임자(Chief Medical Officer)인 Dr. Robert S. Schwartz가 포스터 발표자로 참여하여 Autonomix의 정밀 신경 표적 치료 개발을 강조할 예정입니다.
Autonomix Medical (NASDAQ : AMIX) a annoncé que sa technologie ainsi que les premiers résultats de son étude proof-of-concept seront présentés lors du EuroPCR, une conférence de référence en médecine cardiovasculaire interventionnelle qui se tiendra à Paris, France, du 20 au 23 mai 2025.
La présentation, intitulée « Ablation neurale RF transvasculaire par cathéter pour la douleur sévère du cancer du pancréas – Étude Elpis », sera mise en avant lors du PCR Innovators Day. Le directeur médical de la société, le Dr Robert S. Schwartz, sera l’auteur principal du poster, mettant en lumière les avancées d’Autonomix dans les traitements de précision ciblant les nerfs.
Autonomix Medical (NASDAQ: AMIX) gab bekannt, dass seine Technologie und erste Proof-of-Concept-Studienergebnisse auf dem EuroPCR präsentiert werden, einer führenden Konferenz für interventionelle Herz-Kreislauf-Medizin, die vom 20. bis 23. Mai 2025 in Paris, Frankreich, stattfindet.
Die Präsentation mit dem Titel „Katheterbasierte transvaskuläre RF-Neuralablation bei starken Schmerzen durch Bauchspeicheldrüsenkrebs – Elpis-Studie“ wird am PCR Innovators Day vorgestellt. Der Chief Medical Officer des Unternehmens, Dr. Robert S. Schwartz, wird als präsentierender Autor des Posters die Entwicklungen von Autonomix im Bereich präziser, nervenzielgerichteter Behandlungen hervorheben.
- Company's research selected for presentation at a prestigious international medical conference
- None.
THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France.
Details of the poster presentation are as follows:
Title: Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain Elpis Study
Presenting Author: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.
About EuroPCR
Since 1989, PCR has been providing a wide range of practical solutions for independent post-graduate medical education in the constantly evolving field of interventional cardiology. Coronary interventions, valvular disease, hypertension and stroke, peripheral interventions and heart failure are the main themes covered. In all PCR initiatives, better patient care is systematically placed at the core.
The flagship PCR Course is EuroPCR, which takes place every month of May in Paris, France. This official meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) is acknowledged as the World-Leading Course in Interventional Cardiovascular Medicine, and gathers 11,000+ participants each year.
For more information about EuroPCR 2025 please visit the course website.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
What will Autonomix Medical (AMIX) present at EuroPCR 2025?
When and where is Autonomix Medical's EuroPCR 2025 presentation scheduled?
Who will present Autonomix Medical's research at EuroPCR 2025?
What type of medical technology does AMIX focus on developing?
